Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

ESMO Congress 2022: Industry Sponsored Satellite Symposia – Breast Cancer, Metastatic

ESMO-Congress-2022-1000x250

Friday 9 September

Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

04-Targeting-HER2-Low-Expression-in-Breast-Cancer-PEERVIEW-ONCOLOGY-thumb

Friday, 10:15 - 11:45
View the satellite invitation

SERDs at the Inflection Point in Pretreated ER+/HER- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes with Novel ER-Targeting Therapies

09-SERDs-at-the-Inflection-Point-in-Pretreated-ER-HER-Breast-Cancer-PEERVIEW-ONCOLOGY-thumb

Friday, 18:00 - 19:30
View the satellite invitation

Navigating the Possibilities of Personalised Healthcare in Oncology

10-Navigating-the-Possibilities-of-Personalised-Healthcare-in-Oncology-ROCHE-thumb

Friday, 18:00 - 19:30
View the satellite invitation

Saturday 10 September

Connecting Patients Everywhere to Precision Oncology

23-Connecting-Patients-Everywhere-to-Precision-Oncology-THERMOFISHER-Thumb

Saturday, 18:30 - 20:00
View the satellite invitation

Sunday 11 September

Redefining the Lines of TNBC. Real-World Management: Improving Survival for Patients with Metastatic TNBC

35-Redefining-the-Lines-of-TNBC-Real-World-Management-GILEAD-thumb

Sunday, 13:00 - 14:30
View the satellite invitation

The Current and Emerging Role of ADCs in Cancer Therapy

36-The-Current-and-Emerging-Role-of-ADCs-in-Cancer-Therapy-DAIICHI-Thumb

Sunday, 13:00 - 14:30
View the satellite invitation

Triple Negative Breast Cancer: An Evolving Treatment Landscape

42-Triple-Negative-Breast-Cancer-An-Evolving-Treatment-Landscape-MSD-Thumb

Sunday, 18:30 - 20:00
View the satellite invitation

The Highs and Lows of Breast Cancer Treatment: An Interactive Case-Based Discussion

44-The-Highs-Lows-of-Breast-Cancer-Treatment-An-Interactive-Case-Based-Discussion-Astrazeneca-thumb

Sunday, 18:30 - 20:00
View the satellite invitation

Monday 12 September

Break Expectations: Novel Approaches in Triple-Negative and HR+/HER2- Metastatic Breast Cancer

45-Break-Expectations-GILEAD-thumb

Monday, 13:00 - 14:30
View the satellite invitation

Expert Opinion: Considerations for Managing HER2+ Breast Cancer and Brain Metastases

46-Expert-Opinion-SEAGEN-Thumb

Monday, 13:00 - 14:30
View the satellite invitation

What, Why and How: Expert Review and Opinions on the Potential of Oral SERDs for Our Patients With HR+ BC

50-What-Why-and-How-ROCHE-Thumb

Monday, 13:00 - 14:30
View the satellite invitation

Evidence-Based Practice in HR+/HER2− Advanced Breast Cancer: Illuminating the Treatment Path for Patients

54-Evidence-Based-Practice-in-HR-HER2-ABC-NOVARTIS-Thumb

Monday, 18:30 - 20:00
View the satellite invitation

ER+ / HER2- Breast Cancer: What’s Next for Patients & Providers?

57-ER-HER2-Breast-Cancer-Whats-Next-for-Patients-Providers-thumb

Monday, 18:30 - 20:00
View the satellite invitation

Please note: The European Society for Medical Oncology (ESMO) does not endorse any of the companies, or their products/services, that have sponsored these links.